Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 Diabetes

Kunihiro Suzuki, Masaaki Sagara, Chie Aoki, Seiichi Tanaka, Yoshimasa Aso, Kunihiro Suzuki, Masaaki Sagara, Chie Aoki, Seiichi Tanaka, Yoshimasa Aso

Abstract

Objective The goal of the present study was to investigate the plasma hydrogen sulfide (H2S) levels in patients with type 2 diabetes, as the plasma H2S levels in Japanese patients with type 2 diabetes remain unclear. Methods The plasma H2S levels were measured in 154 outpatients with type 2 diabetes and 66 outpatients without diabetes. All blood samples were collected in the outpatient department from 09:00 to 10:00. The patients had fasted from 21:00 the previous evening and had not consumed alcohol or caffeine or smoked until sample collection. The plasma H2S levels were measured using the methylene blue assay. The plasma H2S levels were determined in triplicate, and the average concentrations were calculated against a calibration curve of sodium sulfide. Results The patients with type 2 diabetes showed a progressive reduction in the plasma H2S levels (45.115.5 M versus 54.026.4 M, p<0.05), which paralleled poor glycemic control. There was a significant correlation between a reduction in the plasma H2S levels and the HbA1c levels (=-0.505, p<0.01), Furthermore, a reduction in the plasma H2S levels was found to be related to a history of cardiovascular diseases in patients with type 2 diabetes (39.913.8 M versus 47.515.9 M, p<0.01). Conclusion Collectively, the plasma H2S levels were reduced in patients with type 2 diabetes, which may have implications in the pathophysiology of cardiovascular disease in diabetic patients. The trial was registered with the University Hospital Medical Information Network (UMIN no. #000020549).

Figures

Figure.
Figure.
The plasma H2S levels in patients with and without type 2 diabetes. (a) A comparison of the patients with and without type 2 diabetes. (b) The influence of glycemic control on the plasma H2S levels. (c) The relationship between a history of cardiovascular disease (CVD) and the plasma H2S levels in patients with type 2 diabetes.

References

    1. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935, 2007.
    1. Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. J Biochem 146: 623-626, 2009.
    1. Módis K, Asimakopoulou A, Coletta C, Papapetropoulos A, Szabo C. Oxidative stress suppresses the cellular bioenergetic effect of the 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. Biochem Biophys Res Commun 433: 401-407, 2013.
    1. Ali MY, Ping CY, Mok YY, et al. . Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol 149: 625-634, 2006.
    1. Yang G, Sun X, Wang R. Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3. FASEB J 18: 1782-1784, 2004.
    1. Suzuki K, Olah G, Módis K, et al. . Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci USA 108: 13829-13834, 2011.
    1. Brancaleone V, Roviezzo F, Vellocco V, De Gruttola L, Bucci M, Cirino G. Biosynthesis of H2S is impaired in non-obese diabetic (NOD) mice. Br J Pharmacol 155: 673-680, 2008.
    1. Whiteman M, Gooding KM, Whatmore JL, et al. . Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 53: 1722-1726, 2010.
    1. Whiteman M, Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J Cell Mol Med 13: 488-507, 2009.
    1. Ali My, Whiteman M, Low CM, Moore PK. Hydrogen sulphide reduces insulin secretion from HIT-T15 cells by a KATP channel-dependent pathway. J Endocrinol 195: 105-112, 2007.
    1. Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 16: 1792-1798, 2002.
    1. Goodwin LR, Francom D, Dieken FP, et al. . Determination of sulfide in brain tissue by gas dialysis/ion chromatography: postmortem studies and two case reports. J Anal Toxicol 13: 105-109, 1989.
    1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980.
    1. Suzuki K, Uchida K, Nakanishi N, Hattori Y. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens 21: 451-457, 2008.
    1. Choi AM, Otterbein LE. Emerging role of carbon monoxide in physiologic and pathophysiologic states. Antioxid Redox Signal 4: 227-228, 2002.
    1. Blackstone E, Morrison M, Roth MB. H2S induces a suspended animation-like state in mice. Science 308: 518, 2005.
    1. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 20: 6008-6016, 2001.
    1. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
    1. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol 156: 713-727, 2009.
    1. Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal 12: 1-13, 2010.
    1. Jha S, Calvert JW, Duranski MR, Ramachandran A, Lefer DJ. Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling. Am J Physiol Heart Circ Physiol 295: H801-H806, 2008.
    1. Fu Z, Liu X, Geng B, Fang L, Tang C. Hydrogen sulfide protects rat lung from ischemia-reperfusion injury. Life Sci 82: 1196-1202, 2008.
    1. Fischer CD, Augustine LM, Maher JM, et al. . Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos 35: 995-1000, 2007.
    1. Matsubara J, Sugiyama S, Akiyama E, et al. . Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circulation 77: 1337-1344, 2013.
    1. Jain SK, Bull R, Rains JL, et al. . Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation? Antioxid Redox Signal 12: 1333-1337, 2010.
    1. Gemici B, Elsheikh W, Feitosa KB, Costa SK, Muscara MN, Wallace JL. H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide 46: 25-31, 2015.
    1. Fiorucci S, Santucci L, Distrutti E. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis 39: 1043-1051, 2007.
    1. Nagy P, Pálinkás Z, Nagy A, Budai B, Tóth I, Vasas A. Chemical aspects of hydrogen sulfide measurements in physiological samples. Biochim Biophys Acta 1840: 876-891, 2014.
    1. Peng H, Cheng Y, Dai C, et al. . A fluorescent probe for fast and quantitative detection of hydrogen sulfide in blood. Angew Chem Int Ed Engl 50: 9672-9675, 2011.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren